India’s PharmEasy is making healthcare accessible to all; valued at $1.5 billion now

PharmEasy is now the first unicorn in India’s online pharmacy space.

India’s PharmEasy is making healthcare accessible to all; valued at $1.5 billion now | BEAMSTART News

PharmEasy, an online medicine delivery startup from India, has raised $350 million led by Prosus Ventures and TPG Growth.

The round also included PharmEasy’s existing investors, which include Temasek, Caisse de dépôt and placement du Québec, LGT Lightrock, Eight Roads, and Think Investments.

The new funding round brings PharmEasy's valuation to $1.5 billion, making it the first unicorn in India's e-pharmacy space.

PharmEasy Application

PharmEasy set out to make healthcare accessible to all

Launched in 2015, PharmEasy helps customers to order medications, healthcare goods, and schedule appointments with laboratories for diagnostic tests through an online mobile application.

The company currently collaborates with over 60,000 local pharmacies and 4,000 physicians, and conducts over 500,000 online telemedicine consultations each month.

PharmEasy makes it easy to buy medicine online.

PharmEasy plans to expand aggressively

Moving forward, PharmEasy plans to use the new funds to further develop supply chains and expand the number of pharmacies under its platform to 200,000 across 100 cities over the course of the next two years.

Furthermore, PharmEasy is already raising funds for its next round, which will value the company at around $1.8 billion.

BEAMSTART is a Global Community and News Portal for Entrepreneurship. We cover the latest news and bring together a global network of CEOs/founders, Investors, Business Leaders, and Professionals.


Download the Community App

Connect with the BEAMSTART Entrepreneurship Community from the palm of your hands. Connect with CEOs/Founders, Investors, Business Leaders, and Professionals. Download below to instantly form partnerships and discover opportunities:

PlayStore ButtonAppStore Button

© 2016 - 2021 BEAMSTART. All Rights Reserved (Legal).